Moderna MRNA
Moderna is a biotechnology company that develops and commercializes medicines and vaccines based on messenger RNA (mRNA), its most well-known product being the COVID-19 vaccine. Moderna trades at 52-week highs (98th percentile) with 463% momentum, but its fundamentals show operating losses (-557% margin) and a valuation that discounts future success not yet reflected in earnings. The melanoma vaccine progress and Middle East expansion are key catalysts, but execution risk and dependence on a single product remain high.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Moderna is a biotechnology company that develops and commercializes medicines and vaccines based on messenger RNA (mRNA), its most well-known product being the COVID-19 vaccine. Moderna trades at 52-week highs (98th percentile) with 463% momentum, but its fundamentals show operating losses (-557% margin) and a valuation that discounts future success not yet reflected in earnings. The melanoma vaccine progress and Middle East expansion are key catalysts, but execution risk and dependence on a single product remain high.
Score by category
| Category | Score |
|---|---|
| Financial health | 5.3 |
| Quality / Moat | 0.7 |
| Valuation | 1.4 |
| Growth | 5.1 |
| Dividend | 1.5 |
| Momentum | 9.8 |
| Risk & Context | 5.3 |
OVERALL SCORE: 3.5/10
Context and risks
Moderna has no direct exposure to rates, oil, or tariffs. The main risk is regulatory and business model: it depends on approval of new products (melanoma vaccine) and on the evolution of demand for its COVID vaccine, with revenue highly concentrated in a single product.
News considered in the analysis
- MRNA Stock Eyes Best Year Ever: Analyst Calls China’s AI Drug Lead ‘Baseless’ As Moderna Awaits Cancer Data — Expectativa por datos de cáncer y defensa frente a competencia china; positivo pero especulativo y parcialmente descontado.
- Why Did AMD, HPE, MRNA Stocks Surge To 52-Week Highs Last Week? — Ruido de mercado; el movimiento ya está en el precio.
- Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts. — Listículo genérico sin información específica sobre Moderna.
- Why Moderna (MRNA) Is Up 29.1% After Melanoma Vaccine Success And Middle East Expansion Talks — Éxito en vacuna de melanoma y expansión en Oriente Medio; material y con probabilidad alta de impacto en ingresos futuros.
- Moderna (MRNA) Held Investment Talks With The UAE Government — Conversaciones de inversión con el gobierno de EAU; potencial positivo pero incierto y no cerrado.
Verdict: Hold; momentum is strong but valuation and current lack of profitability warrant caution until stronger cancer data emerges.
Main risk: Dependence on approval and adoption of new products (melanoma vaccine) and on demand for its COVID vaccine, with highly concentrated revenue and no clear short-term diversification.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →